- $53.65m
- -$46.08m
- $9.85m
Brief: Kronos Bio Announces First Patient Dosed In Phase 1B/2 Clinical Trial Of Lanraplenib In Combination With Gilteritinib In Acute Myeloid Leukemia
Brief: Kronos Bio And Invivoscribe Partner On Companion Diagnostic
Brief: Kronos Bio Reports Recent Business Progress And Second-Quarter 2022 Financial Results
U.S. RESEARCH ROUNDUP-Eli Lilly, Gilead Sciences, Upwork
Kronos Bio Inc reports results for the quarter ended in March - Earnings Summary
Kronos Bio Inc expected to post a loss of 71 cents a share - Earnings Preview
Brief: Kronos Bio Reports Recent Business Progress And First-Quarter 2022 Financial Results
U.S. RESEARCH ROUNDUP-Beigene, Foot Locker, Universal Health Services
Brief: Kronos Bio Announces First Patient Dosed in Phase 3 Study of Entospletinib in Patients With Newly Diagnosed NPM1-mutated Acute Myeloid Leukemi
Brief: Kronos Bio Announces Positive Data From Ongoing Phase 1/2 Trial Of Oral CDK9 Inhibitor KB-0742
Brief: Kronos Bio Appoints Roshawn Blunt To Board Of Directors
Brief: Kronos Bio Inc Files For Mixed Shelf Size Not Disclosed
Brief: Kronos Bio Posts Q3 Loss Per Share Of $0.61
Brief: Kronos Bio, Tempus Report Multi-Year Collaboration
Brief: Kronos Bio To Present Preclinical Data for KB-0742 in Poster Presentation at AACR-NCI-EORTC 2021
Brief: Kronos Bio Reports Recent Business Progress And Second Quarter Financial Results
Kronos Bio Inc reports results for the quarter ended in June - Earnings Summary
Brief: Kronos Bio Announces FDA Clearance Of IND Application For Lanraplenib
Kronos Bio Inc reports results for the quarter ended in March - Earnings Summary